Toll Free: 1-888-928-9744

Viventia Biotechnologies Inc. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Viventia Biotechnologies Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Viventia Biotechnologies Inc. - Product Pipeline Review - 2014', provides an overview of the Viventia Biotechnologies Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Viventia Biotechnologies Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Viventia Biotechnologies Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Viventia Biotechnologies Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Viventia Biotechnologies Inc.'s pipeline products

Reasons to buy

- Evaluate Viventia Biotechnologies Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Viventia Biotechnologies Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Viventia Biotechnologies Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Viventia Biotechnologies Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Viventia Biotechnologies Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Viventia Biotechnologies Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Viventia Biotechnologies Inc. Snapshot 5
Viventia Biotechnologies Inc. Overview 5
Key Information 5
Key Facts 5
Viventia Biotechnologies Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Viventia Biotechnologies Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Viventia Biotechnologies Inc. - Pipeline Products Glance 11
Viventia Biotechnologies Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Viventia Biotechnologies Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Viventia Biotechnologies Inc. - Drug Profiles 15
oportuzumab monatox 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
VB6-845 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
VBX-008 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
VBx-011 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
VBX-050 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Additional Target Programs 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Viventia Biotechnologies Inc. - Pipeline Analysis 22
Viventia Biotechnologies Inc. - Pipeline Products by Target 22
Viventia Biotechnologies Inc. - Pipeline Products by Route of Administration 23
Viventia Biotechnologies Inc. - Pipeline Products by Molecule Type 24
Viventia Biotechnologies Inc. - Pipeline Products by Mechanism of Action 25
Viventia Biotechnologies Inc. - Dormant Projects 26
Viventia Biotechnologies Inc. - Discontinued Pipeline Products 27
Discontinued Pipeline Product Profiles 27
GPI-2A 27
Viventia Biotechnologies Inc. - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30
List of Tables
Viventia Biotechnologies Inc., Key Information 5
Viventia Biotechnologies Inc., Key Facts 5
Viventia Biotechnologies Inc. - Pipeline by Indication, 2014 8
Viventia Biotechnologies Inc. - Pipeline by Stage of Development, 2014 9
Viventia Biotechnologies Inc. - Monotherapy Products in Pipeline, 2014 10
Viventia Biotechnologies Inc. - Phase II, 2014 11
Viventia Biotechnologies Inc. - Phase I, 2014 12
Viventia Biotechnologies Inc. - Preclinical, 2014 13
Viventia Biotechnologies Inc. - Discovery, 2014 14
Viventia Biotechnologies Inc. - Pipeline by Target, 2014 22
Viventia Biotechnologies Inc. - Pipeline by Route of Administration, 2014 23
Viventia Biotechnologies Inc. - Pipeline by Molecule Type, 2014 24
Viventia Biotechnologies Inc. - Pipeline Products by Mechanism of Action, 2014 25
Viventia Biotechnologies Inc. - Dormant Developmental Projects,2014 26
Viventia Biotechnologies Inc. - Discontinued Pipeline Products, 2014 27 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify